



IFW

PATENT
Customer No. 22,852
Attorney Docket No. 03495.0068-10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Luc MONTAGNIER et al.)	Group Art Unit: 1648
)	
Application No.: 09/739,289)	Examiner: Jeffrey S. PARKIN
)	
Filed: December 19, 2000)	
)	Confirmation No.: 3312
For: IMMUNOLOGICAL REAGENTS)	
AND DIAGNOSTIC METHODS)	Notice of Allowance Dated: 06/27/05
FOR THE DETECTION OF)	
HUMAN IMMUNODEFICIENCY)	
VIRUS TYPE 2 UTILIZING)	
MULTIMERIC FORMS OF THE)	
ENVELOPE PROTEINS GP300,)	
P200, AND P90/80)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CORRECTED FILING RECEIPT


We are forwarding herewith a copy of a Filing Receipt for the above-identified patent application. The error is in the Continuing Data as Claimed by Applicant section. As indicated in the attached copy of the Preliminary Amendment filed in the U.S. Patent and Trademark Office on December 19, 2000, Applicants did not claim priority to Application No. 07/804,712. Accordingly, please delete "which is a Con of 07/804,712 12/12/1991 ABN," as shown in red ink on the attached copy of the Official Filing Receipt.


It is respectfully requested that a corrected Filing Receipt be issued as soon as possible.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 27, 2005

By: 
Kenneth J. Meyers
Reg. No. 25,146



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COPY

Sir:

PRELIMINARY AMENDMENT

Prior to examination of the above-identified application, please amend the application as follows:

IN THE TITLE:

Please delete the Title and insert the following therefor:

-- IMMUNOLOGICAL REAGENTS AND DIAGNOSTIC METHODS FOR THE
DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 UTILIZING
MULTIMERIC FORMS OF THE ENVELOPE PROTEINS GP300, P200, AND P90/80--

IN THE SPECIFICATION:

Page 1, please delete lines 2-10 in their entirety, and insert the following therefor:

--This application is a continuation of U.S. Application Serial No. 08/321,566, filed October 27, 1994 (pending), which is a continuation-in-part of U.S. Application Serial No. 08/002,756, filed January 13, 1993, now U.S. Patent No. 5,470,702, which is a division of U.S. Application Serial No. 07/356,459, filed May 25, 1989, now U.S. Patent No. 5,208,321, which is a continuation-in-part of U.S. Application Serial No. 07/204,346, filed June 9, 1988 (abandoned).--

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

IN THE ABSTRACT:

Please delete the Abstract and insert the following therefor:

--Immunological reagents obtained from multimeric forms of the HIV-2 and SIV envelope glycoproteins and their use in the detection of HIV-2, particularly, the HIV-2 proteins gp300, p200, p90, and p80, and gp300 of SIV.--

If any fees are necessary for the submission of these formal drawings, please charge our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Date: December 19, 2000

By: Sean Myers-Payne

Sean Myers-Payne

Reg. No. 42,920

Tel: (202) 408-4000

Fax: (202) 408-4400


Email: sean.myers-

payne@finnegan.com

006121" 58262/60

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000



15m - 5m

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/739,289	12/19/2000	3634	710	3495.0068-10	6	1	1

CONFIRMATION NO. 3312

FILING RECEIPT



OC000000005840383

FINNEGAN, HENDERSON, FARABOW,
GARRETT and DUNNER, L.L.P.
1300 I Street, N.W.
Washington, DC 20005-3315

Date Mailed: 03/08/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Luc Montagnier, Le Plessis Robinson, FRANCE;
Anne G. Laurent-Crawford, Paris, FRANCE;
Bernard Krust, Paris, FRANCE;
Ara G. Hovanessian, Bourg-la-Reine, FRANCE;
Marie-Anne Rey-Cuille, Paris, FRANCE;

Assignment For Published Patent Application

Institut Pasteur, Paris Cedex, FRANCE;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CON OF 08/321,566 10/27/1994 PAT 6,197,496
WHICH IS A CIP OF 08/002,756 01/13/1993 PAT 5,470,702
WHICH IS A DIV OF 07/356,459 05/25/1989 PAT 5,208,321
WHICH IS A CIP OF 07/204,346 06/09/1988 ABN

~~WHICH IS A CON OF 07/804,712 12/12/1991 ABN *~~

(*) Data inconsistent with PTO records.

Foreign Applications

*Dh15
3-12-91
WAX*

If Required, Foreign Filing License Granted 03/06/2001

Projected Publication Date: 06/14/2001

Non-Publication Request: No

Early Publication Request: No

Title

Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins GP300, P200, and P90/80

Preliminary Class

160

Data entry by : MERSO, WOSSENE

Team : OIPE

Date: 03/08/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231